Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210,281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: liu y. Nat Med. 2024 Aug;30(8):2373. doi: 10.1038/s41591-024-03161-w. Nat Med. 2024. PMID: 38956200 No abstract available.
CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer.
Junn JC, Baugnon KL, Lacayo EA, Hudgins PA, Patel MR, Magliocca KR, Corey AS, El-Deiry M, Wadsworth JT, Beitler JJ, Saba NF, Liu Y, Aiken AH. Junn JC, et al. Among authors: liu y. AJNR Am J Neuroradiol. 2017 Feb;38(2):364-370. doi: 10.3174/ajnr.A4993. Epub 2016 Nov 10. AJNR Am J Neuroradiol. 2017. PMID: 28059707 Free PMC article.
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: liu y. Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012550 Free PMC article. Clinical Trial.
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, Anderson AM, Ekpenyong A, Rupji M, Abousaud M, Rudra S, Bates JE, Remick JS, Joshi NP, Woody NM, Awan M, Geiger JL, Shreenivas A, Samsa J, Ward MC, Schmitt NC, Patel MR, Higgins KA, Teng Y, Steuer CE, Shin DM, Liu Y, Ahmed R, Koyfman SA. Saba NF, et al. Among authors: liu y. JAMA Oncol. 2024 Jul 1;10(7):896-904. doi: 10.1001/jamaoncol.2024.1143. JAMA Oncol. 2024. PMID: 38780927 Clinical Trial.
CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.
Kinney BLC, Brammer B, Kansal V, Parrish CJ, Kissick HT, Liu Y, Saba NF, Buchwald ZS, El-Deiry MW, Patel MR, Boyce BJ, Kaka AS, Gross JH, Baddour HM, Chen AY, Schmitt NC. Kinney BLC, et al. Among authors: liu y. Oncoimmunology. 2024 Jun 14;13(1):2367777. doi: 10.1080/2162402X.2024.2367777. eCollection 2024. Oncoimmunology. 2024. PMID: 38887372 Free PMC article.
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: liu y. Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202. Clin Cancer Res. 2024. PMID: 39167623 Clinical Trial.
210,281 results
You have reached the last available page of results. Please see the User Guide for more information.